12.04.2016 • News

Evonik Buys Alkion Biopharma

Germany’s Evonik is strengthening its portfolio of specialty active...
Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. (Lichtmeister/Shutterstock)

Germany’s Evonik is strengthening its portfolio of specialty active ingredients with an agreement to purchase French start-up company Alkion Biopharma for an undisclosed sum. Headquartered in Evry, Alkion specializes in developing biotechnological active ingredients for the cosmetics industry. The company has developed methods to cultivate plant biomass under laboratory conditions and can obtain extracts with an exceptionally high yield of complex ingredients.

The entire process takes place without altering the plant genome and results, said Franck Michoux, Alkion’s founder and CEO, in unique, innovative cosmetic actives. With this acquisition, Evonik can now offer customers highly effective customized plant-based ingredients and product concepts that set themselves apart from competitors, said Tammo Boinowitz, head of Evonik’s personal care business.

The transaction is due to be completed this month. Alkion was originally founded as a spin-off from Imperial College London in 2011.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.